Updated:
CVRx
CVRx, led by Nadim Yared since 2007, commercializes Barostim, an FDA-approved carotid implant for resistant hypertension.
CVRx
Nadim Yared founded CVRx as a private venture in 2001 before joining as CEO in 2007, building it around a contrarian bet that cardiac rhythm management principles could be applied to the autonomic nervous system. The company went public on Nasdaq in 2021, raising $100 million in an IPO that valued the firm at roughly $600 million, and has since scaled its direct sales force to target cardiologists and hypertension specialists across the United States and Europe. The firm's singular asset is Barostim, a pacemaker-like pulse generator and lead system that electrically activates the baroreflex — a major blood-pressure control mechanism — in patients whose hypertension resists three or more drugs. CVRx uses its public-company treasury and occasional debt facilities to fund clinical evidence generation, reimbursement wins, and commercial expansion without committing capital to external startups. Geographic footprint concentrates on the US market, with Germany as a second reimbursement hub following earlier CE Mark adoption. The pivotal BeAT-HF trial, published in the Journal of the American College of Cardiology in 2022, anchored the FDA premarket approval in 2023 and drives a targeted rollout among centers treating heart failure with preserved ejection fraction. CVRx reported Q1 2025 revenue of $14.9 million, up from $11.4 million a year earlier, with an installed base of roughly 350 active implanting centers. No adjacent vehicles or philanthropic structures operate under the firm's control — it is a single-product medical device company that functions as a durable operating business rather than an allocator of third-party capital. In May 2025, the firm secured a $30 million debt facility from Innovatus Capital Partners to extend cash runway and fund commercial scale-up without equity dilution. CVRx's structural differentiator is its status as a publicly traded asset with an unhedged single-product concentration, making it a pure-play bet on neuromodulation adoption rather than a diversified life-sciences portfolio. For family offices and institutional allocators evaluating direct medtech exposure, it represents a rare vehicle where balance-sheet capital is entirely deployed into one regulatory-and-reimbursement pathway.
General information
Firm type
Asset Manager
Year founded
2001
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Minneapolis
Corporate office
Minneapolis, MN, United States
Principals
Nadim Yared
CEO and President
Sector focus
Frequently asked questions
What does CVRx actually sell?
CVRx sells Barostim, an implantable pulse generator and carotid sinus lead that electrically activates the baroreflex to lower blood pressure in patients whose hypertension resists three or more drugs. The FDA approved the device under a premarket approval in 2023 for heart failure patients with reduced ejection fraction, following the pivotal BeAT-HF trial data published in 2022. It is not a drug and not a software therapeutic — it is a surgically placed physical implant.
Who makes investment decisions at the firm?
CVRx is not an investment firm — it is an operating company with a Nasdaq listing (ticker: CVRX). Capital allocation decisions, including the $30 million Innovatus debt facility in 2025 and the 2021 IPO pricing, are governed by CEO Nadim Yared and the board of directors. Institutional investors who take equity positions are buying shares in a single-product medtech business, not committing to a fund.
Is CVRx a single-family office or an investment vehicle for Nadim Yared?
No. CVRx is a publicly traded medical device company, not a family office. Nadim Yared is the CEO and President, not a wealth-origin family principal. The firm has never disclosed any SFO or MFO structure, and its assets are the Barostim intellectual property and commercial infrastructure, not a diversified investment portfolio.
How does CVRx generate returns for investors?
CVRx generates equity returns through revenue growth from Barostim implant procedures and subsequent reimbursement expansion, not through portfolio appreciation or carried interest. As of Q1 2025, quarterly revenue reached $14.9 million, driven by an installed base of roughly 350 active US implanting centers. The investment thesis rests on procedure volume ramp and potential label expansions.
What is the relationship between CVRx and Innovatus Capital Partners?
Innovatus Capital Partners provided a $30 million debt facility to CVRx in May 2025, structured as a loan to extend cash runway for commercial expansion. Innovatus is a lender, not a strategic partner or co-investor. The facility carries interest and repayment obligations typical of life-sciences debt deals, rather than equity conversion rights.
Where is CVRx's core geographic revenue concentration?
CVRx generates the bulk of its revenue from the United States, where the Barostim FDA approval and Medicare reimbursement coverage support a direct sales force targeting cardiology centers. Germany serves as the primary European revenue hub, leveraging earlier CE Mark authorization. The firm has not disclosed material revenue from other regions.
Does CVRx maintain philanthropic or foundation vehicles?
There are no disclosed philanthropic foundations, donor-advised funds, or impact-investment vehicles operated by CVRx or closely held by Nadim Yared in connection with the firm. As a single-product public company, all corporate resources remain allocated to the Barostim commercial pathway.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: